Skip to main content
SpringerLink
Log in

Consider new therapies for the treatment and prevention of Clostridioides difficile infection

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

New therapies to treat and prevent Clostridioides difficile infections (CDI) are needed. CDI requires antibiotic therapy, but this can disrupt gut microbiomes and increase susceptibility to recurrent CDI (rCDI). The search for narrow spectrum, microbiome-sparing antibiotics that can eliminate CDI has been challenging. However, three agents are approved for the prevention of rCDI, including the monoclonal antibody bezlotoxumab and two human donor stool products (rectally administered REBYOTATM and oral VOWSTTM).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gonzales-Luna AJ, Carlson TJ, Garey KW. Emerging options for the prevention and management of Clostridioides difficile infection. Drugs. 2023;83(2):105–16.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jou J, Ebrahim J, Shofer FS, et al. Environmental transmission of Clostridium difficile: association between hospital room size and C. difficile infection. Infect Control Hosp Epidemiol. 2015;36(5):564–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol. 2022;20(5):285–98.

    Article  CAS  PubMed  Google Scholar 

  4. Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124–47.

    Article  CAS  PubMed  Google Scholar 

  5. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–44.

    Article  CAS  PubMed  Google Scholar 

  6. Van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27(Suppl. 2):S1-24.

    Article  PubMed  Google Scholar 

  7. Okhuysen PC, Ramesh M, Garey K, et al. A phase 3, randomized, double-blind study to evaluate the efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridioides difficile infection [abstract no. 730]. Open Forum Infect Dis. 2022;9(Suppl. 2):ofac492.021.

    Article  Google Scholar 

  8. Crestone Inc. CRS3123 for C. difficile infection. 2022. https://crestonepharma.com. Accessed 31 May 2023.

  9. Deinove. The second part of the phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada. 7 Apr 2022. https://www.globenewswire.com.

  10. Garey KW, McPherson J, Dinh AQ, et al. Efficacy, safety, pharmacokinetics, and microbiome changes of ibezapolstat in adults with Clostridioides difficile infection: a phase 2a multicenter clinical trial. Clin Infect Dis. 2022;75(7):1164–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Adis Insight. Ridinilazone - Summit Therapeutics. 2022. https://adisinsight.springer.com. Accessed 31 May 2023.

  12. Acurx Pharmacueticals Inc. Clinical development program. 2023. https://www.acurxpharma.com. Accessed 31 May 23.

  13. US National Library of Medicine. Clinicaltrials.gov. 2023. https://clinicaltrials.gov/ct2/home. Accessed 20 Apr 2023.

  14. MGB Biopharma. News from MGB biopharma. 2021. https://www.prnewswire.com. Accessed 31 May 2023.

  15. Hind C, Clifford M, Woolley C, et al. Insights into the spectrum of activity and mechanism of action of MGB-BP-3. ACS Infect Dis. 2022;8(12):2552–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Garey KW, Rose W, Wilcox MH, et al. Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence. Ann Pharmacother. 2023;57(2):184–92.

    Article  CAS  PubMed  Google Scholar 

  17. ClinicalTrials.gov. Effects of intravenous (IV) omadacycline on gut microbiome. 2023. https://clinicaltrials.gov. Accessed 31 May 2023.

  18. Ehrhardt S, Guo N, Hinz R, et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis. 2016;3(1):ofw011.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16.

    Article  PubMed  PubMed Central  Google Scholar 

  20. US Food and Drug Administration. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies: guidance for industry. 2022. https://www.fda.gov. Accessed 31 May 2023.

  21. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220–9.

    Article  CAS  PubMed  Google Scholar 

  22. Finch Therapeutics. Finch Therapeutics announces decision to discontinue phase 3 trial of CP101 and focus on realizing the value of its intellectual property estate and other assets. 24 Jan 2023. https://ir.finchtherapeutics.com.

  23. Merck Sharp & Dohme LLC. ZINPLAVA - bezlotoxumab injection, solution: US prescribing information. 2016. https://dailymed.nlm.nih.gov. Accessed 31 May 23.

  24. Ferring Pharmaceuticals Inc. REBYOTA - donor human stool suspension: US prescribing information. 2022. https://dailymed.nlm.nih.gov. Accessed 31 May 2023.

  25. Seres Therapeutics Inc. VOWST (fecal microbiota spores, live-brpk) capsules: US prescribing information. 2023. https://www.serestherapeutics.com. Accessed 31 May 2023.

  26. Combacte-Net. Da Volterra receives first authorizations from regulatory authorities in EU countries to initiate its phase 3 clinical trial evaluating the microbiome protector DAV132 in patients with hematologic malignancies. 3 Feb 2021. https://www.combacte.com.

  27. Vehreschild M, Ducher A, Louie T, et al. An open randomized multicentre phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. J Antimicrob Chemother. 2022;77(4):2255–65.

    Article  Google Scholar 

  28. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–17.

    Article  CAS  PubMed  Google Scholar 

  29. Madoff SE, Urquiaga M, Alonso CD, et al. Prevention of recurrent Clostridioides difficile infection: a systematic review of randomized controlled trials. Anaerobe. 2020;61: 102098.

    Article  CAS  PubMed  Google Scholar 

  30. Pfizer Inc. Phase 3 CLOVER trial for Pfizer’s investigational Clostridioides difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints. 1 Mar 2022. https://www.pfizer.com/news.

  31. Bezay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Caroline Fenton & Connie Kang

Authors
  1. Caroline Fenton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Connie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Kang.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

C. Fenton, a contracted employee of Adis International Ltd/Springer Nature, and C. Kang, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenton, C., Kang, C. Consider new therapies for the treatment and prevention of Clostridioides difficile infection. Drugs Ther Perspect 39, 237–242 (2023). https://doi.org/10.1007/s40267-023-01006-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-023-01006-z

Search

Navigation